Administration of a Synthetic Peptide Derived from the E-domain Region of Mechano-Growth Factor Delays Decompensation Following Myocardial Infarction.

Shioura K, Pena J, Goldspink P

International journal of cardiovascular research1 Jun 2014Cited by 3 (Europe PMC)

PMID25606570PMCIDPMC4297642DOI10.4172/2324-8602.1000169PepBankPUB-25606570

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In mice after myocardial infarction, acute-phase delivery of the MGF E-domain peptide ameliorated the decline in hemodynamics.
In plain wordsIn mice after a heart attack, early MGF E-domain peptide lessened the drop in heart performance compared with no treatment.
Peptide
MGF / PEG-MGF
Outcome
IncreaseSystolic and diastolic hemodynamics, acute-phase delivery
Study
mousen: not reported in source
mice after myocardial infarction (MI)
Comparator
Untreated post-MI group
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
Delivery of the E-domain peptide during the acute phase post-MI ameliorated the decline in hemodynamics, delayed decompensation but did not prevent pathologic hypertrophy.
3 context sentences(design, population, supporting numbers)
Summary · context
A significant decline in both systolic and diastolic hemodynamics accompanied by pathologic hypertrophy occurred by 10 weeks post-MI in the untreated group.
Summary · context
Here we deliver the human MGF E-domain peptide to mice during the acute phase (within 12 hours) and the chronic phase (8 weeks) post-MI.
Summary · context
We assessed the impact of peptide delivery on cardiac function and cardiovascular hemodynamics by pressure-volume (P-V) loop analysis and gene expression by quantitative RT-PCR.
Report a problemFND-2560657001
02AnimalAnimal study (in vivo)Efficacy outcome
In mice after myocardial infarction, acute-phase delivery of the MGF E-domain peptide delayed decompensation.
In plain wordsIn mice after a heart attack, early MGF E-domain peptide delayed the point where the heart began to fail.
Peptide
MGF / PEG-MGF
Outcome
DecreaseDecompensation, acute-phase delivery
Study
mousen: not reported in source
mice after myocardial infarction (MI)
Comparator
Untreated post-MI group
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
Delivery of the E-domain peptide during the acute phase post-MI ameliorated the decline in hemodynamics, delayed decompensation but did not prevent pathologic hypertrophy.
2 context sentences(design, population, supporting numbers)
Summary · context
Here we deliver the human MGF E-domain peptide to mice during the acute phase (within 12 hours) and the chronic phase (8 weeks) post-MI.
Summary · context
We assessed the impact of peptide delivery on cardiac function and cardiovascular hemodynamics by pressure-volume (P-V) loop analysis and gene expression by quantitative RT-PCR.
Report a problemFND-2560657002
03AnimalAnimal study (in vivo)Efficacy outcome
In mice after myocardial infarction, acute-phase delivery of the MGF E-domain peptide did not prevent pathologic hypertrophy.
In plain wordsIn mice after a heart attack, early MGF E-domain peptide did not stop harmful heart enlargement.
Peptide
MGF / PEG-MGF
Outcome
No significant changePathologic hypertrophy, acute-phase delivery
Study
mousen: not reported in source
mice after myocardial infarction (MI)
Comparator
Untreated post-MI group
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
Delivery of the E-domain peptide during the acute phase post-MI ameliorated the decline in hemodynamics, delayed decompensation but did not prevent pathologic hypertrophy.
2 context sentences(design, population, supporting numbers)
Summary · context
Here we deliver the human MGF E-domain peptide to mice during the acute phase (within 12 hours) and the chronic phase (8 weeks) post-MI.
Summary · context
We assessed the impact of peptide delivery on cardiac function and cardiovascular hemodynamics by pressure-volume (P-V) loop analysis and gene expression by quantitative RT-PCR.
Report a problemFND-2560657003
04AnimalAnimal study (in vivo)Efficacy outcome
In mice after myocardial infarction, chronic-phase delivery of the MGF E-domain peptide significantly improved systolic function.
In plain wordsIn mice after a heart attack, later MGF E-domain peptide improved the pumping of the heart compared with no treatment.
Peptide
MGF / PEG-MGF
Outcome
IncreaseSystolic function, chronic-phase delivery
Study
mousen: not reported in source
mice after myocardial infarction (MI)
Comparator
Untreated post-MI group
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
Delivery during the chronic phase post-MI significantly improved systolic function, predominantly due to the effects on vascular resistance and prevented decompensation.
2 context sentences(design, population, supporting numbers)
Summary · context
Here we deliver the human MGF E-domain peptide to mice during the acute phase (within 12 hours) and the chronic phase (8 weeks) post-MI.
Summary · context
We assessed the impact of peptide delivery on cardiac function and cardiovascular hemodynamics by pressure-volume (P-V) loop analysis and gene expression by quantitative RT-PCR.
Report a problemFND-2560657004
05AnimalAnimal study (in vivo)Efficacy outcome
In mice after myocardial infarction, chronic-phase delivery of the MGF E-domain peptide prevented decompensation.
In plain wordsIn mice after a heart attack, later MGF E-domain peptide prevented the heart from starting to fail.
Peptide
MGF / PEG-MGF
Outcome
DecreaseDecompensation, chronic-phase delivery
Study
mousen: not reported in source
mice after myocardial infarction (MI)
Comparator
Untreated post-MI group
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
Delivery during the chronic phase post-MI significantly improved systolic function, predominantly due to the effects on vascular resistance and prevented decompensation.
2 context sentences(design, population, supporting numbers)
Summary · context
Here we deliver the human MGF E-domain peptide to mice during the acute phase (within 12 hours) and the chronic phase (8 weeks) post-MI.
Summary · context
We assessed the impact of peptide delivery on cardiac function and cardiovascular hemodynamics by pressure-volume (P-V) loop analysis and gene expression by quantitative RT-PCR.
Report a problemFND-2560657005
06AnimalAnimal study (in vivo)Mechanism
In mice after myocardial infarction, hearts treated with the MGF E-domain peptide showed a significant decline in ANF expression.
In plain wordsIn mice after a heart attack, hearts given MGF E-domain peptide made less of the stress marker ANF.
Peptide
MGF / PEG-MGF
Outcome
DecreaseANF expression in treated hearts
Study
mousen: not reported in source
mice after myocardial infarction (MI)
Comparator
Untreated post-MI group
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
While pathologic hypertrophy persisted there was a significant decline in atrial natriuretic factor (ANF) expression in the E-domain peptide treated hearts.
2 context sentences(design, population, supporting numbers)
Summary · context
Here we deliver the human MGF E-domain peptide to mice during the acute phase (within 12 hours) and the chronic phase (8 weeks) post-MI.
Summary · context
We assessed the impact of peptide delivery on cardiac function and cardiovascular hemodynamics by pressure-volume (P-V) loop analysis and gene expression by quantitative RT-PCR.
Report a problemFND-2560657006
07AnimalAnimal study (in vivo)Efficacy outcome
In mice after myocardial infarction, pathologic hypertrophy persisted despite MGF E-domain peptide treatment.
In plain wordsIn mice after a heart attack, harmful heart enlargement remained despite MGF E-domain peptide treatment.
Peptide
MGF / PEG-MGF
Outcome
No significant changePathologic hypertrophy, chronic-phase delivery
Study
mousen: not reported in source
mice after myocardial infarction (MI)
Comparator
Untreated post-MI group
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
While pathologic hypertrophy persisted there was a significant decline in atrial natriuretic factor (ANF) expression in the E-domain peptide treated hearts.
3 context sentences(design, population, supporting numbers)
Summary · context
Delivery during the chronic phase post-MI significantly improved systolic function, predominantly due to the effects on vascular resistance and prevented decompensation.
Summary · context
Here we deliver the human MGF E-domain peptide to mice during the acute phase (within 12 hours) and the chronic phase (8 weeks) post-MI.
Summary · context
We assessed the impact of peptide delivery on cardiac function and cardiovascular hemodynamics by pressure-volume (P-V) loop analysis and gene expression by quantitative RT-PCR.
Report a problemFND-2560657007

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.